Skip to main content

$0.925 0.030 (3.35%)

High

$0.93

Low

$0.90

Trades

28

Turnover

$33,271

Volume

36,561
30 June 2023 at 4:10pm
Register to track ARX and receive email alerts.
Subject
ARX Ann: Appendix 4G and Corporate Governance Statement

ARX Ann: Annual Report to Shareholders

ARX Ann: Notice of AGM Date and Director Nomination Closing Date

ARX Ann: Investor Presentation

ARX Ann: FY23 Full Year Results Presentation

ARX Ann: FY23 Appendix 4E and Full Year Results

ARX Ann: Notification of Full Year Results Webinar

ARX Ann: Investor Presentation

ARX Ann: March 2023 Quarterly Report and Appendix 4C

ARX Ann: Notification of Quarterly Results Webinar

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: AROA secures first FDA clearance for ENIVO system

ARX Ann: Release of Shares from Voluntary Escrow

ARX Ann: Change of Director's Interest Notice - SE

ARX Ann: Change of Director's Interest Notice - JP

ARX Ann: Change of Director's Interest Notice - JM

ARX Ann: Change of Director's Interest Notice - BW

ARX Ann: Change of Director's Interest Notice - PM

ARX Ann: Change of Director's Interest Notice - JD

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: Aroa awarded agreement with Premier Inc

ARX Ann: Application for quotation of securities - ARX

ARX Ann: Section 708A Notice

ARX Ann: Investor Presentation

ARX Ann: December 2022 Quarterly Report and Appendix 4C

ARX Ann: Notification of Quarterly Results Webinar

ARX Ann: Notification of cessation of securities - ARX

ARX Ann: Notification of cessation of securities - ARX

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: Change of Director's Interest Notice - JD

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: Section 708A Notice

ARX Ann: Application for quotation of securities - ARX

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: Aroa Half Year Results Presentation

ARX Ann: Aroa Biosurgery Half Yearly Results H1 FY23

ARX Ann: Appendix 4D and Half Year Report

ARX Ann: Notification regarding unquoted securities - ARX

ARX Ann: Appendix 3G

ARX Ann: Notification of Half Year Results Webinar

ARX Ann: Initial Director's Interest Notice - CM

ARX Ann: Change of Registry Address

ARX Ann: Becoming a substantial holder

ARX Ann: Investor Presentation

ARX Ann: September 2022 Quarterly Report and Appendix 4C

ARX Ann: Notification of Quarterly Webinar

ARX Ann: Pre-Clinical Study of Enivo Shows Potential

ARX Ann: Notification of cessation of securities - ARX

ARX Ann: Dr Catherine Mohr to join Aroa Board

ARX Ann: Change of Director's Interest Notice - JD

Register to track ARX and receive email alerts.